Stock listing
Euronext:ALBPS Biophytis SA Action
Home listing (Euronext) of Biophytis SA
Follow Biophytis SA into a list and get an email when it puts out news.
Share price · EURONEXT:ALBPS
€0.03 EUR -0.00 (-1.9%)
Close on Nov 20, 2026
- Day range
- €0.03 – €0.034 EURNov 20, 2026
- Volume
- 17.20M sharesNov 20, 2026
- Market cap
- €11.37M EURAt the close on Nov 20, 2026 · price × 373.9M shares outstanding
- 52-week range
- €0.0042 – €0.16 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €1.57M EURMedian day 16.09M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Euronext:ALBPS · Home | €0.03 EUR | -0.001 (-1.9%) | 17,195,832 | €0.032 | €0.034 | €0.03 | €0.031 | Close on Nov 20, 2026 |
| OTC:BPTSY | $0.40 USD | 0.00 (0.0%) | 3,000 | $0.40 | $0.40 | $0.40 | $0.40 | Close on Nov 6, 2026 |
| Frankfurt:6XB3 | €0.01 EUR | -0.001 (-5.5%) | — | €0.012 | €0.012 | €0.01 | €0.011 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · EURONEXT:ALBPS · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.03 | -0.001 | -1.9% | €0.032 | €0.034 | €0.03 | 17,195,832 | |
| €0.031 | -0.003 | -8.6% | €0.033 | €0.033 | €0.03 | 11,775,643 | |
| €0.034 | -0.001 | -2.3% | €0.033 | €0.034 | €0.033 | 7,533,397 | |
| €0.035 | -0.003 | -7.0% | €0.037 | €0.039 | €0.033 | 14,991,847 | |
| €0.037 | -0.002 | -5.1% | €0.039 | €0.041 | €0.037 | 14,940,936 | |
| €0.039 | -0.002 | -4.4% | €0.042 | €0.043 | €0.037 | 14,937,156 | |
| €0.041 | 0.00 | -0.5% | €0.042 | €0.044 | €0.038 | 14,019,801 | |
| €0.041 | -0.004 | -8.0% | €0.046 | €0.046 | €0.04 | 22,973,867 | |
| €0.045 | +0.003 | +5.9% | €0.054 | €0.056 | €0.043 | 80,443,120 | |
| €0.042 | +0.002 | +5.5% | €0.04 | €0.045 | €0.038 | 39,875,120 | |
| €0.04 | +0.00 | +1.0% | €0.043 | €0.055 | €0.04 | 143,391,109 | |
| €0.04 | +0.014 | +54.3% | €0.029 | €0.041 | €0.027 | 121,304,578 | |
| €0.026 | -0.003 | -9.8% | €0.03 | €0.03 | €0.024 | 17,847,652 | |
| €0.029 | -0.002 | -7.1% | €0.031 | €0.031 | €0.028 | 10,821,724 | |
| €0.031 | -0.003 | -7.8% | €0.033 | €0.033 | €0.03 | 10,345,226 | |
| €0.033 | -0.001 | -1.5% | €0.034 | €0.034 | €0.032 | 8,905,764 | |
| €0.034 | 0.00 | -0.6% | €0.035 | €0.035 | €0.033 | 5,886,298 | |
| €0.034 | +0.00 | +0.6% | €0.035 | €0.036 | €0.034 | 5,886,746 | |
| €0.034 | -0.001 | -2.0% | €0.035 | €0.038 | €0.033 | 14,255,852 | |
| €0.035 | +0.003 | +8.8% | €0.033 | €0.038 | €0.032 | 27,447,766 | |
| €0.032 | -0.002 | -6.5% | €0.034 | €0.034 | €0.032 | 8,162,707 | |
| €0.034 | +0.00 | +1.2% | €0.034 | €0.036 | €0.03 | 14,269,925 | |
| €0.034 | -0.006 | -14.9% | €0.039 | €0.04 | €0.025 | 37,404,281 | |
| €0.04 | 0.00 | -0.8% | €0.041 | €0.041 | €0.038 | 5,864,453 | |
| €0.04 | -0.003 | -6.1% | €0.041 | €0.042 | €0.04 | 7,740,076 | |
| €0.042 | -0.002 | -3.6% | €0.043 | €0.043 | €0.04 | 11,166,215 | |
| €0.044 | -0.002 | -3.9% | €0.046 | €0.048 | €0.043 | 11,918,285 | |
| €0.046 | 0.00 | -0.9% | €0.046 | €0.047 | €0.046 | 3,366,189 | |
| €0.046 | -0.003 | -5.1% | €0.048 | €0.049 | €0.046 | 7,231,203 | |
| €0.049 | +0.002 | +4.1% | €0.045 | €0.049 | €0.045 | 10,797,186 | |
| €0.047 | -0.001 | -2.5% | €0.049 | €0.049 | €0.045 | 7,025,761 | |
| €0.048 | +0.001 | +2.1% | €0.046 | €0.058 | €0.046 | 30,325,488 | |
| €0.047 | -0.001 | -1.9% | €0.048 | €0.048 | €0.046 | 5,414,183 | |
| €0.048 | +0.003 | +5.7% | €0.047 | €0.05 | €0.046 | 9,521,121 | |
| €0.045 | -0.002 | -4.2% | €0.047 | €0.048 | €0.045 | 9,090,593 | |
| €0.047 | -0.002 | -3.5% | €0.049 | €0.05 | €0.047 | 14,819,902 | |
| €0.049 | -0.005 | -9.3% | €0.051 | €0.054 | €0.048 | 18,483,826 | |
| €0.054 | +0.008 | +16.1% | €0.048 | €0.054 | €0.047 | 35,367,328 | |
| €0.047 | 0.00 | 0.0% | €0.046 | €0.048 | €0.044 | 12,247,614 | |
| €0.047 | -0.002 | -3.5% | €0.048 | €0.048 | €0.046 | 6,348,009 | |
| €0.048 | -0.002 | -4.2% | €0.049 | €0.051 | €0.047 | 6,160,604 | |
| €0.05 | +0.003 | +6.3% | €0.047 | €0.051 | €0.046 | 13,317,239 | |
| €0.047 | -0.002 | -3.5% | €0.049 | €0.049 | €0.046 | 12,384,409 | |
| €0.049 | -0.002 | -3.4% | €0.049 | €0.053 | €0.048 | 11,802,698 | |
| €0.051 | -0.001 | -1.0% | €0.054 | €0.056 | €0.049 | 18,180,805 | |
| €0.051 | +0.005 | +11.8% | €0.046 | €0.054 | €0.045 | 34,017,773 | |
| €0.046 | -0.005 | -9.8% | €0.05 | €0.05 | €0.045 | 19,660,420 | |
| €0.051 | +0.001 | +1.6% | €0.05 | €0.055 | €0.047 | 29,071,721 | |
| €0.05 | -0.002 | -4.8% | €0.055 | €0.056 | €0.049 | 20,038,447 | |
| €0.053 | -0.014 | -21.4% | €0.052 | €0.058 | €0.05 | 84,912,781 | |
| €0.067 | -0.001 | -1.3% | €0.068 | €0.074 | €0.064 | 14,077,169 | |
| €0.068 | -0.005 | -6.6% | €0.078 | €0.079 | €0.067 | 25,012,223 | |
| €0.073 | +0.002 | +3.6% | €0.07 | €0.081 | €0.064 | 46,236,371 | |
| €0.07 | -0.007 | -9.2% | €0.08 | €0.08 | €0.068 | 37,513,793 | |
| €0.077 | +0.00 | +0.5% | €0.078 | €0.095 | €0.068 | 94,655,180 | |
| €0.077 | +0.024 | +44.2% | €0.057 | €0.077 | €0.052 | 82,404,945 | |
| €0.053 | +0.001 | +1.1% | €0.05 | €0.057 | €0.044 | 39,703,402 | |
| €0.053 | -0.005 | -9.5% | €0.061 | €0.061 | €0.049 | 26,502,721 | |
| €0.058 | +0.006 | +10.9% | €0.052 | €0.074 | €0.052 | 66,045,617 | |
| €0.052 | -0.012 | -18.8% | €0.065 | €0.065 | €0.052 | 33,285,340 | |
| €0.065 | -0.01 | -13.5% | €0.074 | €0.074 | €0.062 | 34,365,914 | |
| €0.075 | -0.005 | -6.8% | €0.09 | €0.092 | €0.072 | 31,612,416 | |
| €0.08 | +0.001 | +1.0% | €0.079 | €0.096 | €0.066 | 58,715,879 | |
| €0.079 | -0.026 | -24.6% | €0.094 | €0.095 | €0.078 | 46,221,801 | |
| €0.105 | -0.021 | -16.7% | €0.117 | €0.118 | €0.099 | 34,738,602 | |
| €0.126 | -0.006 | -4.5% | €0.132 | €0.141 | €0.095 | 60,377,586 |
Splits
1 split · EURONEXT:ALBPS · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-400 | Consolidation |
- Ticker
- Euronext:ALBPS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Euronext
- Currency
- EUR
What changed lately
Latest news release · Nov 12, 2026
Assemblée générale du 12 novembre 2026: quorum non atteint - Convocation d’une seconde assemblée générale le 27 novembre 2026
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 19 slides
Latest news
Assemblée générale du 12 novembre 2026: quorum non atteint - Convocation d’une seconde assemblée générale le 27 novembre 2026
Nov 12, 2026
Closed €0.039 (-4.4%) on Nov 12, 2026
Biophytis announces the operational launch of its joint venture in China
Nov 9, 2026
Closed €0.045 (+5.9%) on Nov 9, 2026
Biophytis reports first- half 2026 results and provides an update on its strategy
Oct 30, 2026
Closed €0.031 (-7.8%) on Oct 30, 2026
Chairman\'s Letter - General Meeting Invitation
Oct 22, 2026
Closed €0.032 (-6.5%) on Oct 22, 2026
Biophytis S A ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Sep 11, 2026
Closed €0.053 (-21.4%) on Sep 11, 2026
Biophytis S A to evaluate BIO101’s potential to limit weight regain in its OBA clinical study in obesity
Sep 9, 2026
Closed €0.068 (-6.6%) on Sep 9, 2026
Biophytis S A strengthens its financial position and extends its cash runway into Q1 2027
Aug 31, 2026
Closed €0.058 (+10.9%) on Aug 31, 2026
Biophytis S A PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE
Aug 3, 2026
Closed €0.04 (+525.0%) on Aug 3, 2026
Information on annual financial statements
Apr 29, 2026
Closed €0.021 (-12.9%) on Apr 30, 2026
Biophytis S A PRESENTS ITS DEVELOPMENT PROGRAMS IN OBESITY AND SARCOPENIA AT THE ICFSR CONFERENCE
Mar 13, 2026
Closed €0.032 (-0.3%) on Mar 13, 2026
Biophytis SA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 17 in the last 12 months · 28 in all · newest Nov 12, 2026 · oldest 2025
- Decks
- 35 decks · latest August 2026
Where Biophytis SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Euronext:ALBPS · Home listing · This page | Euronext | France | EUR |
| LSE:0D1W | LSE | United Kingdom | EUR |
| LS Exchange:A403QV | LS Exchange | Germany | EUR |
| OTC:BPTSY | OTC | United States | USD |
| Lang & Schwarz:A403QV | Lang & Schwarz | Germany | EUR |
| gettex:6XB3 | gettex | Germany | EUR |
| Frankfurt:6XB3 | Frankfurt | Germany | EUR |
| Munich:6XB3 | Munich | Germany | EUR |
| Turquoise:ALBPSP | Turquoise | United Kingdom | EUR |
| Stuttgart:6XB3 | Stuttgart | Germany | EUR |
Valuation
balance Jun 30, 2025 · price Nov 20, 2026
- Enterprise value
- €17.72M EUR
- P/E
- Not reported
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Biophytis SA · EURONEXT:ALBPS | US$12.47M | US$19.44M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Bolt Biotherapeutics, Inc. · NASDAQ:BOLT | US$12.80M | US$18.89M | n/a | 7.5× | n/a | 1.5× | n/a | 2.4× | 0.52 |
| Avai Bio, Inc. · OTC:AVAI | US$12.79M | US$12.67M | n/a | n/a | n/a | n/a | n/a | n/a | 0.28 |
| Neuphoria Therapeutics Inc. · NASDAQ:NEUP | US$12.72M | −US$6.03M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 0.61 |
| Seres Therapeutics, Inc. · NASDAQ:MCRB | US$12.64M | US$30.89M | n/a | 14.5× | n/a | 0.6× | n/a | 1.7× | 1.21 |
| Passage Bio, Inc. · NASDAQ:PASG | US$12.61M | −US$7.55M | n/a | n/a | n/a | 252× | n/a | 0.0× | 1.94 |
| Allarity Therapeutics, Inc. · NASDAQ:ALLR | US$12.56M | US$21.48M | n/a | 61.4× | n/a | n/a | n/a | n/a | 1.40 |
| Lobe Sciences Ltd · CSE:LOBE | US$12.52M | US$8.89M | n/a | n/a | n/a | 9.5× | n/a | 0.0× | 0.31 |
| MIRA Pharmaceuticals, Inc. · NASDAQ:MIRA | US$12.23M | US$5.26M | n/a | n/a | n/a | 1.8× | n/a | 0.0× | 1.48 |
| Genflow Biosciences PLC · LSE:GENF | US$12.06M | US$11.23M | n/a | n/a | n/a | 48.5× | n/a | 0.0× | n/a |
| Xintela AB · OMXSTO:XINT | US$11.89M | US$11.82M | n/a | 39.8× | n/a | n/a | n/a | n/a | n/a |
| Median of the others | US$12.59M | US$11.52M | 27.2× | 1.8× | 0.0× | 0.91 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 2.20 EUR · Analysts' mean
- EPS, year to Dec 2025
- -1.89 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Stanislas VEILLET | Chairman – CEO |
| Christophe COURTILLAT | Chief Financial Officer |
| Waly DIOH | Chief Operating Officer |
| Edouard BIETH | Chief Strategy Officer |
| Pierre J. DILDA | Chief Scientific Officer |
| Pr. Jean MARIANI | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Stanislas VEILLET | Chairman – CEO |
| Claude ALLARY | |
| Nadine COULM | |
| Pr. Jean MARIANI | Chief Medical Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Dec 31, 2025 | Feb 23, 2026 | −5.2% |
| Quarter to Sep 30, 2025 | Oct 31, 2025 | −2.6% |
| Q2 2025 | Sep 29, 2025 · Before open | −3.5% |
| Quarter to Mar 31, 2025 | May 30, 2025 | −2.3% |
| Q4 2024 | Mar 31, 2025 | −2.8% |
| Quarter to Sep 30, 2024 | Nov 27, 2024 | +2.4% |
| Q2 2024 | Sep 30, 2024 | −0.0% |
| Q1 2024 | Apr 8, 2024 | −3.6% |
| Q4 2023 | Feb 26, 2024 | −2.4% |
| Q3 2023 | Oct 23, 2023 · After close | −4.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Jul 21, 2023 · Before open | −1.4% |
| Q1 2023 | Apr 18, 2023 · Before open | −10.3% |
| Q4 2022 | Feb 27, 2023 | +5.8% |
| Q3 2022 | Oct 31, 2022 · After close | −2.1% |
| Q1 2022 | May 26, 2022 · After close | +0.1% |
| Q4 2021 | Feb 26, 2022 | +4.0% |
| Q3 2021 | Dec 1, 2021 | −6.3% |
| Q2 2021 | Sep 17, 2021 · Before open | −0.6% |
| Q1 2021 | May 20, 2021 | +4.9% |
| Q4 2020 | Feb 26, 2021 · Before open | +4.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 19 slides | August 2026 |
| Investor Presentation (August 2026) | Investor deck | 19 slides | August 2026 |
| Investor Presentation (March 2026) | Investor deck | 21 slides | March 2026 |
| Investor Presentation (March 2026) | Investor deck | 21 slides | March 2026 |
| Investor Presentation (January 2025) | Investor deck | 32 slides | January 2025 |
| Investor Presentation (December 2024) | Investor deck | 48 slides | Dec 6, 2024 |
| Investor Presentation (May 2024) | Investor deck | 43 slides | May 2024 |
| Investor Presentation (May 2024) | Investor deck | 43 slides | May 2024 |
| Investor Presentation (January 2024) | Investor deck | 25 slides | January 2024 |
| Investor Presentation (January 2024) | Investor deck | 25 slides | January 2024 |
All 35 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2023) | Investor deck | 25 slides | November 2023 |
| Investor Presentation (September 2023) | Investor deck | 25 slides | September 2023 |
| American Thoracic Society 2023 | Conference | 13 slides | May 24, 2023 |
| Investor Presentation (June 2022) | Investor deck | 10 slides | Jun 3, 2022 |
| Investor Presentation (June 2022) | Investor deck | 10 slides | Jun 3, 2022 |
| Shareholder Meeting (May 2021) | Shareholder meeting | 26 slides | May 10, 2021 |
| Shareholder Meeting (May 2021) | Shareholder meeting | 27 slides | May 10, 2021 |
| Shareholder Meeting (April 2021) | Shareholder meeting | 16 slides | Apr 26, 2021 |
| Shareholder Meeting (April 2021) | Shareholder meeting | 16 slides | Apr 26, 2021 |
| IPO Roadshow (February 2021) | IPO roadshow | 18 slides | Feb 3, 2021 |
| Investor Presentation (February 2021) | Investor deck | 29 slides | February 2021 |
| Investor Presentation (February 2021) | Investor deck | 29 slides | February 2021 |
| Investor Presentation (January 2021) | Investor deck | 29 slides | January 2021 |
| Investor Presentation (January 2021) | Investor deck | 29 slides | January 2021 |
| Investor Presentation (March 2020) | Investor deck | 33 slides | March 2020 |
| Investor Presentation (January 2020) | Investor deck | 33 slides | Jan 27, 2020 |
| ICFSR 2020 | Conference | 13 slides | 2020 |
| Investor Presentation (September 2019) | Investor deck | 27 slides | September 2019 |
| IPO Roadshow (July 2019) | IPO roadshow | 32 slides | Jul 9, 2019 |
| ICFSR 2019 Biophytis Lunch Industry Symposium | Conference | 21 slides | Feb 21, 2019 |
| ICFSR 2018 Miami | Conference | 23 slides | March 2018 |
| JPM 2018 | Conference | 31 slides | January 2018 |
| EURETINA 2017 | Conference | 6 slides | September 2017 |
| Investor Presentation (June 2016) | Investor deck | 27 slides | June 2016 |
| Investor Presentation (June 2016) | Investor deck | 27 slides | June 2016 |
Financials
Annual, in EUR
Income statement
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 298.0K | 803.0K | 484.0K | 311.0K | 280.0K | 262.0K | 227.0K | 204.0K | 167.0K | 65.0K |
| Gross profit | -298.0K | -803.0K | -484.0K | -311.0K | -280.0K | -262.0K | -227.0K | -204.0K | -167.0K | -65.0K |
| Research and development | 4.47M | 10.4M | 16.0M | 19.7M | 9.92M | 9.09M | 9.51M | 7.04M | 5.12M | 1.57M |
| Selling, general and administrative | 5.12M | 5.49M | 7.24M | 7.15M | 4.02M | 6.59M | 4.35M | 2.87M | 2.82M | 3.07M |
| Operating income | -8.50M | -14.3M | -23.3M | -26.8M | -13.9M | -15.7M | -13.9M | -9.91M | -7.94M | -3.10M |
| Depreciation and amortization | 298.0K | 803.0K | 484.0K | 311.0K | 280.0K | 262.0K | 227.0K | 204.0K | 167.0K | 65.0K |
| EBITDA | -8.20M | -13.5M | -22.8M | -26.5M | -13.7M | -15.4M | -13.6M | -9.70M | -7.78M | -3.03M |
| Interest expense | 872.0K | 1.25M | 1.60M | 4.43M | 4.37M | 2.53M | 185.0K | 3.29M | 35.0K | 172.5K |
| Income before tax | -10.4M | -18.6M | -24.2M | -31.2M | -25.5M | -17.8M | -14.1M | -11.4M | -7.95M | -3.29M |
| Income tax | -1.15M | -1.56M | -3.41M | 2.28M | -3.33M | -28.0K | -72.0K | 1.50M | 13.0K | 65.0K |
| Net income | -10.4M | -17.0M | -24.2M | -33.5M | -25.5M | -18.9M | -14.0M | -11.4M | -7.95M | -5.23M |
| Earnings per share, basic | -2.00 | -12.54 | -55.40 | -113.38 | -170.19 | -448.88 | -418.32 | -496.65 | -512.93 | -430.09 |
Balance sheet
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 78.0K | 5.57M | 11.1M | 23.9M | 5.85M | 6.34M | 14.4M | 19.9M | 3.07M | 9.41M |
| Short-term investments | 190.0K | 368.0K | 590.0K | 1.23M | 12.5M | 475.0K | 5.00M | 10.0M | 367 | |
| Receivables | 3.47M | 2.74M | 5.36M | 5.12M | 5.21M | 7.85M | 4.69M | 3.33M | 2.67M | 1.19M |
| Inventory | 45.0K | 1.57M | -709.0K | 29.0K | 46.0K | 160.0K | 212.4K | |||
| Current assets | 3.92M | 8.85M | 18.6M | 31.4M | 24.0M | 14.7M | 19.4M | 23.4M | 5.89M | 10.8M |
| Property, plant and equipment | 231.0K | 315.0K | 584.0K | 563.0K | 114.0K | 185.0K | 295.0K | 313.0K | 276.0K | 194.0K |
| Total assets | 6.90M | 12.0M | 22.0M | 36.3M | 27.2M | 17.7M | 21.9M | 25.9M | 8.39M | 13.5M |
| Accounts payable | 4.28M | 5.39M | 6.94M | 7.61M | 7.99M | 7.87M | 4.87M | 2.40M | 1.92M | 701.0K |
| Current liabilities | 15.6M | 12.4M | 19.3M | 22.8M | 22.9M | 19.7M | 8.28M | 3.94M | 2.91M | 1.42M |
| Long-term debt | 673.0K | 2.42M | 4.18M | 6.07M | 1.83M | 5.40M | 6.38M | 661.0K | 820.0K | 272.0K |
| Total debt | 9.84M | 8.27M | 14.6M | 17.6M | 9.10M | 15.2M | 8.20M | 1.01M | 1.09M | 802.8K |
| Total liabilities | 16.6M | 15.8M | 23.9M | 30.6M | 20.4M | 25.2M | 14.9M | 4.76M | 3.87M | 1.85M |
| Shareholders' equity | -9.67M | -3.86M | -1.88M | 5.83M | 2.30M | -7.54M | 7.04M | 21.2M | 4.55M | 11.7M |
| Shares outstanding | 5.19M | 1.36M | 437.1K | 295.7K | 149.9K | 42.2K | 33.4K | 23.0K | 15.5K | 12.2K |
Cash flow
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -8.64M | -12.9M | -19.0M | -23.8M | -9.86M | -15.3M | -12.1M | -8.73M | -6.63M | -3.21M |
| Capital spending | -9.15M | -220.0K | -141.0K | -344.0K | -214.0K | -282.0K | -113.0K | -128.0K | -129.0K | -6.19K |
| Free cash flow | -8.64M | -13.1M | -19.1M | -24.1M | -10.1M | -15.6M | -12.2M | -8.86M | -6.76M | -3.22M |
| Cash from investing | 10.0K | 370.0K | -17.0K | 12.2M | -12.7M | -278.0K | -104.0K | -128.0K | -129.0K | -6.19K |
| Cash from financing | 3.14M | 7.03M | 6.13M | 29.7M | 22.0M | 7.50M | 6.77M | 25.6M | 407.0K | 12.6M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Share buybacks | 5.54M | 16.6M | 23.5M | 21.8M | -280.0K | 12.3M | ||||
| Change in cash | -5.49M | -5.49M | -12.9M | 18.1M | -490.0K | -8.07M | -5.45M | 16.8M | -6.34M | 9.42M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Assemblée générale du 12 novembre 2026 : quorum non atteint - Convocation d’une seconde assemblée générale le 27 novembre 2026 | Nov 12, 2026 | Other filings | Euronext |
| BIOPHYTIS ANNOUNCES THE OPERATIONAL LAUNCH OF ITS JOINT VENTURE IN CHINA | Nov 9, 2026 | Operations update | Euronext |
| BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY | Oct 30, 2026 | Other filings | Euronext |
| Chairman\'s Letter - General Meeting Invitation | Oct 22, 2026 | Other filings | Euronext |
Cap table
Built by 6ix from Biophytis SA’s releases
- Common shares
- 373,853,783
- Fully diluted
- 373,853,783
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 373,853,783 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 373,853,783 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Christophe COURTILLAT | Chief Financial Officer · Since at least Nov 5, 2026 |
| Claude ALLARY | Director · Since at least Nov 5, 2026 |
| Edouard BIETH | Chief Strategy Officer · Since at least Nov 5, 2026 |
| Nadine COULM | Director · Since at least Nov 5, 2026 |
| Pierre J. DILDA | Chief Scientific Officer · Since at least Nov 5, 2026 |
| Pr. Jean MARIANI | Chief Medical Officer · Since at least Nov 5, 2026 |
| Stanislas VEILLET | Chairman – CEO · Since at least Nov 5, 2026 |
| Waly DIOH | Chief Operating Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Biophytis SA.